POWERED BY SOFTWARE
There is a recognized need to standardize thermal ablation techniques and improve local tumor control. Achieving an optimal minimal ablation margin (MAM) is the most relevant factor in influencing local tumor control and it is the only one that is modifiable during the thermal ablation procedure.1 Software-based approaches have been shown to improve the precision of ablation margin evaluation when compared to visual assessments, ultimately enhancing clinical outcomes and promoting consistent, accountable practice across institutions.2
RaySearch’s history of working in close collaboration with leading cancer centers to bring scientific advancements faster to the clinical world helped us bring our image-guided thermal ablation confirmation solution to life. By combining deformable image registration with Deep Learning Segmentation (DLS), our solution delivers state-of-the-art ablation treatments through automated and streamlined workflows.
PROVEN BY OUTCOMES
More than 25 years of innovation – RaySearch’s mission is clear: to provide innovative software that continuously improves cancer treatment and expands possibilities in interventional oncology. Through relentless innovation, close collaboration with leading cancer centers, and a strong focus on research and development, RaySearch empowers medical teams to deliver the highest quality of care. RaySearch’s software is used and trusted by nearly 1,200 clinics in 54 countries, including some of the world's leading cancer centers.
Optimal ablation margins are essential to achieve local tumor control when leveraging thermal ablation as a therapeutic approach to cancer care. A randomized phase 2 trial1 compared the minimal ablative margin in patients with liver tumors using our advanced image-guided ablation solution versus the margins from traditional visual assessment. Software-based assessment achieved optimal ablation margins in 84% of cases. This translated into a considerable reduction in local tumor progression with 96% of patients treated with the software-based assessment showing no local tumor progression.